Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes
British Journal of Haematology · 2025-09 · 207 (3) · 824-833
DOI: 10.1111/bjh.20225 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 25.06.2025. Verfasst von Philippa Johnstone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Mycosis Fungoides, Skin Neoplasms, Cell Transformation, Neoplastic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Large‐cell transformation of mycosis fungoides (LCTMF) is rare, histologically distinct, with an aggressive clinical course; yet is not recognised as an independent entity in classification systems nor in staging systems for mycosis fungoides and Sézary syndrome (MF/SS). Herein, the patterns of care and survival outcomes for patients with LCTMF are described, with prognosis compared to published data of non‐transformed MF/SS. Eligibility required clinicopathological diagnosis of LCTMF (1/1/1990–31/10/2021), managed at Peter MacCallum Cancer Centre. Eighty‐three patients were eligible. Median follow‐up was 8.0 years. At the time of LCTMF, 36% had early‐stage MF (IA‐IIA), 76% had cutaneous‐only LCTMF. The most common first‐line treatments were localised radiotherapy (48%) and multiagent chemotherapy (23%). Median overall survival (OS) from LCTMF diagnosis was 3.5 years (95% [confidence interval] CI: 2.2–8.2). Three prognostic groups of LCTMF were identified: unifocal cutaneous only, multifocal cutaneous only and extracutaneous (median OS: 4.6, 2.5 and 1.1 years, respectively; p = 0.005). Unfavourable prognostic factors were advanced age and extracutaneous LCTMF. In conclusion, treatment pathways for patients with LCTMF were varied, and prognosis was poor, despite >1/3 having early‐stage MF. However, differences in prognosis were suggested, with unifocal cutaneous LCTMF associated with greater OS. Given prognostic differences from MF/SS, consideration to include LCTMF in staging systems is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
- Department of Radiation Oncology, Cork University Hospital, Cork, Ireland.
- Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Philippa Johnstone, Martin Higgins, H Miles Prince, Carrie van der Weyden, Piers Blombery, Belinda A Campbell
Zitieren
APA
Johnstone, P., Higgins, M., Prince, H. M., Lade, S., McCormack, C., van der Weyden, C., Bhabha, F., Buelens, O., Blombery, P., & Campbell, B. A. (2025). Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes. British Journal of Haematology, 207(3), 824-833. https://doi.org/10.1111/bjh.20225
Vancouver
Johnstone P, Higgins M, Prince HM, Lade S, McCormack C, van der Weyden C, et al. Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes. British Journal of Haematology. 2025;207(3):824-833. doi:10.1111/bjh.20225
BibTeX
@article{Johnstone2025,
author = {Johnstone, Philippa and Higgins, Martin and Prince, H Miles and Lade, Stephen and McCormack, Chris and van der Weyden, Carrie and Bhabha, Friyana and Buelens, Odette and Blombery, Piers and Campbell, Belinda A},
title = {Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {3},
pages = {824--833},
doi = {10.1111/bjh.20225}
}
EUVIMED